Top Tweets for #CHECKMATE9ER
An integrative analysis of circulating and tumor microenvironment determinants of patient response in the #CheckMate9ER trial of nivolumab and cabozantinib in advanced #RenalCellCarcinoma. Presentation by @BraunMDPhD @YaleMed. #ASCO25 written coverage by @RKSayyid @USC > https://t.co/VEPnElWHrc @ASCO
💫Kidney Clinical Science Symposium #ASCO25
👉Abs4511: Dr @BraunMDPhD presenting analysis of circulating 🩸and TME 🔬 for response to Cabo/Nivo on #CheckMate9ER
🩺Clinical implications:
- Cabo/Nivo responses enriched in TME w/ high VICM anti-tumor macrophage), high PD-L1, high plasma, and low circulating Treg
Further Reading
📖 Biomarker-informed care for patients with renal cell carcinoma @mb_mckinnon @DrScottHaake
🔗 https://t.co/lcyLc5zMLU
--------------------------------------------------------
n = 150 (23% of ITT)
🧫 PD-L1 staining
🩸 4 PBMC markers
🔬 4 ECM markers
🔬 7 H&E HIF features.
♦️ECM marker VICM (fragment of vimentin measures macrophage activity and immune status) was prognostic across both therapies.
♦️Log regression models that integrated highly informatic features had AUCs of 0.76 for NIVO+CABO model and 0.72 for the SUN model.
NIVO+CABO arm determinants of response
✅high VICM (anti-tumor macrophage polarization)
✅high PD-L1
✅high plasma cell #
✅high cancer cell # at the epithelial stromal interface
👇low circulating (Pro-C6)
👇low % circulating Treg (Foxp3+ CD4+)
👥@DrChoueiri @montypal @KKellySci @tompowles1 @brian_rini @BraunMDPhD @HHammersMD @PBarataMD @PavlosMsaouel @yekeduz_emre @DrYukselUrun @ReneeSaliby @drenriquegrande @bavilima @DRBakaloudiMD @nataliagandur @crisbergerot @kidneycan @KidneyCancer @ASCO @oncoalert @OncBrothers
🔥CheckMate 9ER: Nova era no carcinoma renal com @nataliagandur!
✅+42% de redução no risco de progressão/morte
✅Sobrevivência global: 46,5 meses
✅Taxa de resposta: 55,7%
📲Leia mais: https://t.co/svFjnS5kCC
#Oncologia #CheckMate9ER #ASCOGU25 #CarcinomaRenal
Nivolumab + cabozantinib vs sunitinib for previously untreated advanced #RenalCellCarcinoma: Final follow-up results from the #CheckMate9ER trial. Presentation by @motzermd @MSKCancerCenter. #GU25 written coverage by @RKSayyid @USC > https://t.co/fRiA9xSD0S
@Larvol Quick Takes: At @ASCO - #GU25, Speaking to @brunolarvol, Dr. @DrYukselUrun talks about CheckMate 9ER trial.
#LARVOL #GUCancer #CheckMate9ER #Oncology #CancerResearch
Final #CheckMate9ER results (5+ yr FU: N+C > S in 1L #aRCC
PFS HR 0.58, OS HR 0.79, ORR 55.7% vs 27.4%. No new safety signals. N+C remains a SOC for untreated aRCC.
@ASCO #GU25 @motzermd @tompowles1 @MSKCancerCenter @OncoAlert
#GU25 @DanaFarber researchers present groundbreaking findings in #GUCancer! @DrChoueiri @VincentWenxinXu
🔹 New HIF-2α inhibitor shows promise in #RCC
🔹 KIM-1 as a biomarker for monitoring post-immunotherapy
🔹 Final follow-up of #CheckMate9ER confirms long-term benefit of nivolumab + cabozantinib
📅 Feb 13-15 | #KidneyCancer #Immunotherapy @ASCO #ASCOGU25
#ReadNow Details on UroToday > https://t.co/sAe7d35fej
🔬 Exciting insights from #CheckMate9ER! @CaPsurvivorship @DanaFarber interviews @BraunMDPhD @YaleCancer on novel glycoproteomic biomarkers for #KidneyCancer. Key findings: higher glycosylation linked to worse outcomes, and specific glycosylation events may predict response to Nivolumab + Cabozantinib. Promising steps toward new biomarker strategies! #WatchNow > https://t.co/C5u6OzctXt
🔬 Exciting insights from #CheckMate9ER! @CaPsurvivorship @DanaFarber interviews @BraunMDPhD @YaleCancer on novel glycoproteomic biomarkers for #KidneyCancer. Key findings: higher glycosylation linked to worse outcomes, and specific glycosylation events may predict response to Nivolumab + Cabozantinib. Promising steps toward new biomarker strategies! #WatchNow > https://t.co/C5u6OzctXt
🔬 Exciting insights from #CheckMate9ER! @CaPsurvivorship @DanaFarber interviews @BraunMDPhD @YaleCancer on novel glycoproteomic biomarkers for #KidneyCancer. Key findings: higher glycosylation linked to worse outcomes, and specific glycosylation events may predict response to Nivolumab + Cabozantinib. Promising steps toward new biomarker strategies! #WatchNow > https://t.co/C5u6OzctXt
🔬 Exciting insights from #CheckMate9ER! @CaPsurvivorship @DanaFarber interviews @BraunMDPhD @YaleCancer on novel glycoproteomic biomarkers for #KidneyCancer. Key findings: higher glycosylation linked to worse outcomes, and specific glycosylation events may predict response to Nivolumab + Cabozantinib. Promising steps toward new biomarker strategies! #WatchNow > https://t.co/C5u6OzctXt
🔬 Exciting insights from #CheckMate9ER! @CaPsurvivorship @DanaFarber interviews @BraunMDPhD @YaleCancer on novel glycoproteomic biomarkers for #KidneyCancer. Key findings: higher glycosylation linked to worse outcomes, and specific glycosylation events may predict response to Nivolumab + Cabozantinib. Promising steps toward new biomarker strategies! #WatchNow > https://t.co/C5u6OzctXt
Novel serum glycoproteomic biomarkers predict response to nivolumab + cabozantinib vs sunitinib in advanced #RCC: analysis from #CheckMate9ER. Presentation by @BraunMDPhD @YaleCancer. #ESMO24 written coverage by @chavarriagaj > https://t.co/OuXoSSTxcf
#CheckMate9ER gives a ✔️ to potential novel #biomarker in assessing #advanced #RCC treatment in new #ESMO24 #data from @BraunMDPhD 📈.
🔎 Learn more: https://t.co/snyUjgOggw
Excellent analysis by our very own @CharleneMantia of survival states over 4 years in #CheckMate9ER comparing 1L Nivo + Cabo vs. Sun in pts w/ aRCC! #ASCO24
➡️ Over the 4-year period since initiation of 1L therapy, the longer OS with Nivo+Cabo was accompanied by 1.5 times longer mTFS before 2L therapy vs. Sun (7 vs 4.6 mo).
@ASCO @DanaFarber_GU @OncoAlert
Cabozantinib and nivolumab combination therapy show durable efficacy in advanced #KidneyCancer. María Bourlon, MD, MSc joins @PBarataMD @caseccc to discuss #CheckMate9ER 55-month follow-up, revealing the enduring benefits of cabo + nivo over sunitinib > https://t.co/LGHMGkjsOo
Cabozantinib and nivolumab combination therapy show durable efficacy in advanced #KidneyCancer. María Bourlon, MD, MSc joins @PBarataMD @caseccc to discuss #CheckMate9ER 55-month follow-up, revealing the enduring benefits of cabo + nivo over sunitinib > https://t.co/LGHMGkjsOo
Cabozantinib and nivolumab combination therapy show durable efficacy in advanced #KidneyCancer. María Bourlon, MD, MSc joins @PBarataMD @caseccc to discuss #CheckMate9ER 55-month follow-up, revealing the enduring benefits of cabo + nivo over sunitinib > https://t.co/LGHMGkjsOo
🌟 Catch our latest video with @tompowles1 discussing #KEYNOTE564, #CheckMate9ER, and more #RCC updates! 🌟 Watch now: https://t.co/6YKg13QoJ5
A panel featuring Drs. @DrRanaMcKay, Nizar Tannir, @katy_beckermann, and @HHammersMD highlighted the #CheckMate9ER study and implications for clinical practice in #RCC. Watch Now: https://t.co/GGSCUmRall
Last Seen Hashtags on Sotwe
gaywarsaw
Seen from Poland
بوتوم
Seen from Netherlands
hataycuckold
Seen from Turkey
ชอบเห็นแฟนโดนเย็ด
Seen from Thailand
lồn dâm
Seen from Vietnam
zayndom
Seen from Brazil
kelsimonroe
Seen from Qatar
nude
Seen from Germany
desi #shemale
Seen from United Kingdom
momson(((())))***+filter:native_video
Seen from United States
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.7M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.3M followers
Taylor Swift
@taylorswift13
82.1M followers
Lady Gaga
@ladygaga
73.7M followers
Virat Kohli
@imvkohli
70.9M followers
Kim Kardashian
@kimkardashian
70.1M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.2M followers
Neymar Jr
@neymarjr
63.7M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.3M followers
X
@x
60.8M followers